Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Partial Onset Seizures
Secondarily Generalized Seizures
Primary Generalized Tonic-Clonic Seizures

Interventions

DRUG: Perampanel

Sponsor

Eisai Inc.